226 related articles for article (PubMed ID: 31518649)
1. Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis.
Perelas A; Glennie J; van Kerkhove K; Li M; Scheraga RG; Olman MA; Culver DA
Pulm Pharmacol Ther; 2019 Dec; 59():101839. PubMed ID: 31518649
[TBL] [Abstract][Full Text] [Related]
2. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
[TBL] [Abstract][Full Text] [Related]
3. An updated safety review of the drug treatments for idiopathic pulmonary fibrosis.
Sgalla G; Comes A; Richeldi L
Expert Opin Drug Saf; 2021 Sep; 20(9):1035-1048. PubMed ID: 33881959
[TBL] [Abstract][Full Text] [Related]
4. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
Flaherty KR; Fell CD; Huggins JT; Nunes H; Sussman R; Valenzuela C; Petzinger U; Stauffer JL; Gilberg F; Bengus M; Wijsenbeek M
Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946005
[TBL] [Abstract][Full Text] [Related]
5. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis.
Jouneau S; Crestani B; Thibault R; Lederlin M; Vernhet L; Valenzuela C; Wijsenbeek M; Kreuter M; Stansen W; Quaresma M; Cottin V
Respir Res; 2020 Nov; 21(1):312. PubMed ID: 33239000
[TBL] [Abstract][Full Text] [Related]
6. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
Proesmans VLJ; Drent M; Elfferich MDP; Wijnen PAHM; Jessurun NT; Bast A
Lung; 2019 Oct; 197(5):551-558. PubMed ID: 31440832
[TBL] [Abstract][Full Text] [Related]
7. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.
Ogura T; Taniguchi H; Azuma A; Inoue Y; Kondoh Y; Hasegawa Y; Bando M; Abe S; Mochizuki Y; Chida K; Klüglich M; Fujimoto T; Okazaki K; Tadayasu Y; Sakamoto W; Sugiyama Y
Eur Respir J; 2015 May; 45(5):1382-92. PubMed ID: 25504994
[TBL] [Abstract][Full Text] [Related]
9. The safety of new drug treatments for idiopathic pulmonary fibrosis.
Fletcher S; Jones MG; Spinks K; Sgalla G; Marshall BG; Limbrey R; Richeldi L
Expert Opin Drug Saf; 2016 Nov; 15(11):1483-1489. PubMed ID: 27532218
[TBL] [Abstract][Full Text] [Related]
10. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
Maher TM; Strek ME
Respir Res; 2019 Sep; 20(1):205. PubMed ID: 31492155
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and safety of treatment switch from Pirfenidone to Nintedanib in patients with idiopathic pulmonary fibrosis: a real-world observational study.
Ntolios P; Archontogeorgis K; Anevlavis S; Bonelis K; Paxinou N; Voulgaris A; Froudarakis M; Steiropoulos P
Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6326-6332. PubMed ID: 34730213
[TBL] [Abstract][Full Text] [Related]
12. Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?
Hayton C; Chaudhuri N
Drugs Aging; 2017 Sep; 34(9):647-653. PubMed ID: 28861727
[TBL] [Abstract][Full Text] [Related]
13. [Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
Markart P; Drakopanagiotakis F; Wygrecka M
Dtsch Med Wochenschr; 2021 Feb; 146(3):181-184. PubMed ID: 33513653
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series.
Delanote I; Wuyts WA; Yserbyt J; Verbeken EK; Verleden GM; Vos R
BMC Pulm Med; 2016 Nov; 16(1):156. PubMed ID: 27863518
[TBL] [Abstract][Full Text] [Related]
15. Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
Sathiyamoorthy G; Sehgal S; Ashton RW
South Med J; 2017 Jun; 110(6):393-398. PubMed ID: 28575896
[TBL] [Abstract][Full Text] [Related]
16. Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust.
Casillo V; Cerri S; Ciervo A; Stendardo M; Manzoli L; Flacco ME; Manno M; Bocchino M; Luppi F; Boschetto P
BMC Pulm Med; 2019 Sep; 19(1):170. PubMed ID: 31488107
[TBL] [Abstract][Full Text] [Related]
17. Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study.
Oishi K; Hirano T; Murata Y; Hamada K; Uehara S; Suetake R; Yamaji Y; Asami-Noyama M; Edakuni N; Ohata S; Utsunomiya T; Sakamoto K; Onoda H; Matsumoto T; Matsunaga K; Yano M
Ther Adv Respir Dis; 2019; 13():1753466619872890. PubMed ID: 31476961
[TBL] [Abstract][Full Text] [Related]
18. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.
Maher TM; Molina-Molina M; Russell AM; Bonella F; Jouneau S; Ripamonti E; Axmann J; Vancheri C
BMC Pulm Med; 2017 Sep; 17(1):124. PubMed ID: 28915874
[TBL] [Abstract][Full Text] [Related]
19. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
Galli JA; Pandya A; Vega-Olivo M; Dass C; Zhao H; Criner GJ
Respirology; 2017 Aug; 22(6):1171-1178. PubMed ID: 28317233
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
Corral M; DeYoung K; Kong AM
BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]